CIBC Asset Management Inc Raises Holdings in Merck & Co., Inc. (MRK)

CIBC Asset Management Inc grew its position in Merck & Co., Inc. (NYSE:MRK) by 172.6% during the 4th quarter, Holdings Channel reports. The firm owned 921,517 shares of the company’s stock after acquiring an additional 583,511 shares during the quarter. CIBC Asset Management Inc’s holdings in Merck & Co., Inc. were worth $51,854,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. NewSquare Capital LLC increased its holdings in shares of Merck & Co., Inc. by 728.3% during the 3rd quarter. NewSquare Capital LLC now owns 14,801 shares of the company’s stock valued at $115,000 after acquiring an additional 13,014 shares during the last quarter. Balentine LLC increased its holdings in shares of Merck & Co., Inc. by 1.0% during the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock valued at $135,000 after acquiring an additional 20 shares during the last quarter. WealthTrust Arizona LLC increased its holdings in shares of Merck & Co., Inc. by 103.7% during the 4th quarter. WealthTrust Arizona LLC now owns 2,495 shares of the company’s stock valued at $140,000 after acquiring an additional 1,270 shares during the last quarter. Risk Paradigm Group LLC increased its holdings in shares of Merck & Co., Inc. by 748.1% during the 2nd quarter. Risk Paradigm Group LLC now owns 2,256 shares of the company’s stock valued at $145,000 after acquiring an additional 1,990 shares during the last quarter. Finally, Acrospire Investment Management LLC increased its holdings in shares of Merck & Co., Inc. by 212.5% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,500 shares of the company’s stock valued at $160,000 after acquiring an additional 1,700 shares during the last quarter. 74.60% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

Shares of Merck & Co., Inc. stock opened at $53.41 on Friday. Merck & Co., Inc. has a 52 week low of $53.12 and a 52 week high of $66.41. The firm has a market capitalization of $145,917.80, a P/E ratio of 57.43, a P/E/G ratio of 2.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.06 and a current ratio of 1.33.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.04. Merck & Co., Inc. had a return on equity of 28.61% and a net margin of 6.40%. The firm had revenue of $10.43 billion during the quarter, compared to the consensus estimate of $10.48 billion. During the same quarter in the prior year, the company earned $0.89 EPS. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. equities analysts forecast that Merck & Co., Inc. will post 4.17 earnings per share for the current year.

Merck & Co., Inc. announced that its Board of Directors has approved a share buyback program on Tuesday, November 28th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 6th. Shareholders of record on Thursday, March 15th will be given a $0.48 dividend. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.59%. Merck & Co., Inc.’s dividend payout ratio is currently 206.45%.

In other Merck & Co., Inc. news, insider Weir Mirian M. Graddick sold 60,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $61.63, for a total value of $3,697,800.00. Following the completion of the sale, the insider now owns 101,484 shares in the company, valued at approximately $6,254,458.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Weir Mirian M. Graddick sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $58.00, for a total value of $290,000.00. Following the completion of the sale, the insider now owns 101,484 shares of the company’s stock, valued at approximately $5,886,072. The disclosure for this sale can be found here. Insiders sold a total of 82,500 shares of company stock valued at $5,026,025 in the last quarter. Corporate insiders own 0.25% of the company’s stock.

A number of brokerages have recently commented on MRK. Jefferies Group set a $55.00 price objective on Merck & Co., Inc. and gave the company a “hold” rating in a report on Friday. Leerink Swann raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating in a report on Monday, March 12th. BMO Capital Markets set a $65.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, March 8th. Credit Suisse Group lowered their price objective on Merck & Co., Inc. from $66.00 to $65.00 and set an “outperform” rating on the stock in a report on Wednesday, February 14th. Finally, DZ Bank raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Tuesday, February 13th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $66.35.

ILLEGAL ACTIVITY NOTICE: “CIBC Asset Management Inc Raises Holdings in Merck & Co., Inc. (MRK)” was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3298500/cibc-asset-management-inc-raises-holdings-in-merck-co-inc-mrk.html.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$0.70 Earnings Per Share Expected for Republic Services  This Quarter
$0.70 Earnings Per Share Expected for Republic Services This Quarter
WEC Energy Group  Receives Media Impact Rating of 0.31
WEC Energy Group Receives Media Impact Rating of 0.31
Welltower  Receiving Favorable Press Coverage, Report Shows
Welltower Receiving Favorable Press Coverage, Report Shows
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact IHS Markit  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact IHS Markit Stock Price
Somewhat Favorable News Coverage Somewhat Unlikely to Impact Coca-Cola European Partners  Stock Price
Somewhat Favorable News Coverage Somewhat Unlikely to Impact Coca-Cola European Partners Stock Price
Karmacoin Price Up 16% Over Last 7 Days
Karmacoin Price Up 16% Over Last 7 Days


© 2006-2018 Ticker Report. Google+.